The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients

Publié le 31 mars 2022 - Journal of Neuro-Oncology

Auteurs : Charles de Marcellus, Arnault Tauziède-Espariat, Aurélie Cuinet, Claudia Pasqualini, Matthieu Robert, Kevin Beccaria, Stéphanie Puget, Nathalie Boddaert, Dominique Figarella-Branger, Emilie de Carli, Franck Bourdeaut, Pierre Leblond, Fanny Fouyssac, Nicolas Andre, Anne Bertozzi, Thibaut Butel, Christelle Dufour, Dominique Valteau-Couanet, Pascale Varlet, Jacques Grill

Voir la publication sur HAL DOI

Introduction : At least half of children with low-grade glioma (LGG) treated with first line chemotherapy experience a relapse/progression and may therefore need a second-line chemotherapy. Irinotecan-bevacizumab has been recommended in this setting in France after encouraging results of pilot studies. We performed a retrospective analysis to define the efficacy, toxicity and predictors for response to the combination on a larger cohort.Methods : We reviewed the files from children